We are thrilled to inform you that, effective September 7th, XPOVIO® (selinexor) in combination with bortezomib and dexamethasone (XVd) for the treatment of adult patients with multiple myeloma who have received at least one prior therapy, is now funded in Ontario, since September 7, as wells as in Nova Scotia and British Columbia since October 1st!

Please see the following links for full funding criteria:

• Ontario
• Nova Scotia
• British Columbia (under the MYBSD protocol: Lymphoma & Myeloma)